Clinical Trial

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

Study acronym: Z+RCHOP/RDHAP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.
Trial Details
NCT Number NCT06255704
Lead Sponsor Shanxi Province Cancer Hospital
Conditions Mantle Cell Lymphoma
Enrollment 23 participants
Start Date 2024-03-15
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-13